Vemurafenib induced clinical response in more than half of patients with previously treated BRAF V600E–mutant metastatic melanoma.
Vemurafenib significantly improved survival at 6 months in patients with metastatic melanoma in the BRIM-3 trial, but its effectiveness in patients previously treated with other drugs and its longer-term efficacy were undetermined. Investigators conducted this updated, phase 2 trial of vemurafenib in 132 patients with BRAF V600–mutant metastatic melanoma who had received other prior treatment.
In the median follow-up period of 12.9 months, the overall response rate was 53% (6% had a complete response). Median response duration was 6.7 months, and median progression-free survival was 6.8 months. Median overall survival was 15.9 months (95% CI, 11.6 to 18.3 mos.). Primary progression occurred in 14% of patients. Although the V600E mutation is …
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)